- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00677391
Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population
May 13, 2008 updated by: Abbott
Randomized Trial of Obese Non-Diabetic Malaysians Using Sibutramine: A Randomized Double-Blind Placebo-Controlled Study of Sibutramine in the Management of Obese Subjects in Malaysia
The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
103
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The subject did not adequately respond (i.e., did not achieve or maintain > 5%weight loss) to an appropriate non-pharmacologic weight-reducing regimen (i.e., diet and exercise) within 3 months prior to Screening.
- The subject was male or female and between 18 and 65 years of age.
- The subject has nutritional obesity and BMI >= 27 kg/m2 associated with dyslipidemia or has BMI >= 30 kg/m2.
Dyslipidemia was defined as having at least one of the following three conditions:
- Low-density lipoprotein (LDL)-cholesterol level of > 3.4 mmol/L (> 130 mg/dL)
- total cholesterol level of > 5.2 mmol/L (> 200 mg/dL)
- triglyceride level of > 1.7 mmol/L (> 150 mg/dL). 254
If the subject was female
- she must either not of childbearing potential: defined as postmenopausal for at least 2 years or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy),
- or was of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)on contraceptives (oral or parenteral) for the 3-month period prior to Week 0, a vasectomized partner, total abstinence from sexual intercourse
- If the subject was female, the results of a urine pregnancy test performed at Screening and Week 0 were negative.
- If the subject was female, the subject was not breast-feeding.
- The subject was judged to be in general good health based upon the results of medical history, complete physical examination and clinical laboratory tests.
- The subject was not taking any over-the-counter or prescription drugs, or herbal products for weight loss during the 4 week period prior to Screening.
- The subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to undertaking any study-specific procedures
Exclusion Criteria:
- History or evidence according to the 1997 American Diabetic Association (ADA)26criteria of type 1 or type 2 diabetes mellitus, i.e., fasting plasma glucose level >= 7.0 mmol/L.
- Inadequately controlled hypertension having systolic blood pressure >= 145 mmHg or diastolic blood pressure >= 90 mmHg (average of three measurements) or any hypertensive subjects taking > 3 medications to control blood pressure.
- History of Gilles de la Tourette's Syndrome.
Use within 4 weeks prior to Week 0 of any of the following:
- Monoamine oxidase inhibitors (MAOIs): used to treat depression and Parkinson's disease.
- Medications that regulate the neurotransmitter serotonin in the brain (SSRIs): used to treat psychiatric disorders and to stop smoking.
- Amino acids: used to treat sleep disorders.
- Certain antimigraine drugs (such as sumatriptan, dihydroergotamine).
- Opioids (such as pentazocine, pethidine, fentanyl, dextromethorphan).
- Organic causes of obesity (e.g., hypothyroidism).
- History of major eating disorders, such as anorexia nervosa or bulimia nervosa.
- History of benign prostatic hyperplasia with urinary retention.
- History of neurological disorders such as seizures.
- History of documented psychiatric illnesses such as anxiety, depression, bipolar disorder or schizophrenia or having psychotic symptoms.
- History or evidence of severe renal or hepatic impairments.
- History of narrow-angle glaucoma.
- History of coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, arrhythmia or cerebrovascular disease (transient ischemic attacks or strokes).13. History or evidence of hyperthyroidism.
- Persistent tachycardia at rest, i.e., heart rate >100 bpm (average of 3 measurements).
- History of primary or secondary pulmonary hypertension.
- Underlying or suspected phaeochromocytoma.
- Known hypersensitivity to sibutramine hydrochloride monohydrate or any other component of the product.
- Known history of drug or alcohol abuse.
- Has previous history with the use of sibutramine.
- Any other medical illnesses judged by the investigator that may compromise the efficacy or safety of sibutramine.
- Unlikely to cooperate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
|
Capsules, once daily
|
Active Comparator: 1
|
Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in bodyweight from baseline to final evaluation
Time Frame: Wk 0, then, bi-weekly through duration of study
|
Wk 0, then, bi-weekly through duration of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of change in body weight from baseline to final evaluation.
Time Frame: Wk 0 and Wk 24
|
Wk 0 and Wk 24
|
Total body fat mass, total body lean mass, percent of total body lean mass measurements (Bodystat® 1500)
Time Frame: Wks 0, 12 and 24
|
Wks 0, 12 and 24
|
Total Abdominal Fat Mass, Total Abdominal Lean Mass, Percent of Total Abdominal Fat Mass and Percent of Total Abdominal Lean Mass (DEXA Scan)
Time Frame: Wk 0 and Wk 24
|
Wk 0 and Wk 24
|
metabolic measurements (Cholesterol, Triglycerides & Insulin resistance) and SF 36 Quality of life measurement
Time Frame: Wk 0, 12 and Wk 24. In addition to the stated time frames, a Quality of life survey was conducted 30 days post study.
|
Wk 0, 12 and Wk 24. In addition to the stated time frames, a Quality of life survey was conducted 30 days post study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2002
Primary Completion (Actual)
November 1, 2004
Study Registration Dates
First Submitted
May 12, 2008
First Submitted That Met QC Criteria
May 13, 2008
First Posted (Estimate)
May 14, 2008
Study Record Updates
Last Update Posted (Estimate)
May 14, 2008
Last Update Submitted That Met QC Criteria
May 13, 2008
Last Verified
May 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MLAY-02-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Sibutramine
-
GlaxoSmithKlineCompleted
-
Merck Sharp & Dohme LLCCompleted
-
AbbottTerminated
-
AbbottCompleted
-
AbbottCompleted
-
Mayo ClinicCompletedObesity | OverweightUnited States
-
AbbottCompletedObesity | Binge Eating Disorder
-
Eisai LimitedCompleted
-
AbbottCompleted
-
Mayo ClinicNational Institutes of Health (NIH)CompletedObesityUnited States